Editorial: Advances in chemotherapy-resistant hepatocellular carcinoma, volume II DOI Creative Commons
Shui Liu, Yufan Liu,

Mo Sha

et al.

Frontiers in Medicine, Journal Year: 2025, Volume and Issue: 12

Published: March 27, 2025

Intrahepatic cholangiocarcinoma (ICC) is the second most common primary malignant tumor of liver after HCC, and surgical resection only potentially curative treatment (Jiang et al., 2025). However, ICC characterized by high malignancy a pronounced tendency for postoperative recurrence, there currently lack standardized methods adjuvant therapy (Peng A secondary study Sun al. (Sun 2024) reviews strategies through retrospective review recent studies clinical trials, focusing on effectiveness, challenges, potential development directions treatment. The article points out that beneficiaries therapy, patients with lymph node metastasis positive margins are considered ideal candidates therapy. Other high-risk factors include multiple tumors, low differentiation, size over 5 cm, vascular nerve invasion, elevated CA19-9 levels. Regarding chemotherapy, although have shown chemotherapy beneficial highrisk patients, no consensus. interim results BILCAP trial indicate capecitabine has become recommended drug CCA (Primrose 2019). selection regimens still requires further prospective studies. radiotherapy ICC, data supporting ICC. With advancement medical science in-depth understanding molecular level more effective may be provided in future.Another Xiang (Xiang mainly focuses research progress resistance models HCC. researchers comprehensively establishment applications HCC models, including traditional vitro vivo patient-derived direct detection drug-resistant samples from transgenic (Figure 1). It also discusses main mechanisms discovered based these provides model basis possible future personalized They found easier to establish corresponding experimental higher stability reproducibility. individual differences gene expression could reflected; retain characteristics crucial studying pathways related different subtypes; simpler method screening genes; editing can used generate gene-engineered cell lines or animal specific drugs. Therefore, appropriate should selected purpose actual environment.He colleagues (He 2024b)focus radiological influence untreatable progression (UP) time UP (TTUP) local regional interventional This included who received drug-eluting bead TACE (DEB-TACE) hospital January 2017 December 2022. Multivariate logistic regression analysis shows age (OR: 0.950, p=0.044), initial response 0.177, p=0.020), regimen 7.133, p=0.007) three independent risk UP, had greatest impact occurrence UP. Cox total bilirubin (HR: 1.029, p=0.002), distribution 1.752, p=0.034), SACE classification 0.668, p=0.043), number 1.130, p=0.004), 0.539, p=0.019), 4.615, p<0.001) variables affecting TTUP. TTUP was significantly longer than without (329 days vs. 166 days, p<0.05). best (279 130 Subjective Angiographic Chemoembolization Endpoint (SACE) affected TTUP, III IV grades those I II (269 533 70 144 Tumor multi-lobed tumors shorter single-lobed tumors.In years, targeted immunotherapy made significant (Bloom 2025;Hu For instance, drugs targeting FGFR2, IDH1/2, etc. good efficacy trials (Capuozzo 2022;Vogel 2023;He 2024a). Immunotherapy, especially immune checkpoint inhibitors, such as PD-1/PD-L1 demonstrated great (Huang 2025;Liang Local (such TACE, ablation, radioembolization) plays an important role advanced cancer. By optimizing plans, combined ablation effect improved survival period prolonged. In addition, image-guided precise reduce complications improve patient tolerance. Based patient's genetic characteristics, biological behavior features, plans will direction. Through collaboration multidisciplinary teams, considering comprehensively, suitable strategy quality life patients. continuous technology deepening collaboration, diagnosis cancer witness breakthroughs future.

Language: Английский

Editorial: Advances in chemotherapy-resistant hepatocellular carcinoma, volume II DOI Creative Commons
Shui Liu, Yufan Liu,

Mo Sha

et al.

Frontiers in Medicine, Journal Year: 2025, Volume and Issue: 12

Published: March 27, 2025

Intrahepatic cholangiocarcinoma (ICC) is the second most common primary malignant tumor of liver after HCC, and surgical resection only potentially curative treatment (Jiang et al., 2025). However, ICC characterized by high malignancy a pronounced tendency for postoperative recurrence, there currently lack standardized methods adjuvant therapy (Peng A secondary study Sun al. (Sun 2024) reviews strategies through retrospective review recent studies clinical trials, focusing on effectiveness, challenges, potential development directions treatment. The article points out that beneficiaries therapy, patients with lymph node metastasis positive margins are considered ideal candidates therapy. Other high-risk factors include multiple tumors, low differentiation, size over 5 cm, vascular nerve invasion, elevated CA19-9 levels. Regarding chemotherapy, although have shown chemotherapy beneficial highrisk patients, no consensus. interim results BILCAP trial indicate capecitabine has become recommended drug CCA (Primrose 2019). selection regimens still requires further prospective studies. radiotherapy ICC, data supporting ICC. With advancement medical science in-depth understanding molecular level more effective may be provided in future.Another Xiang (Xiang mainly focuses research progress resistance models HCC. researchers comprehensively establishment applications HCC models, including traditional vitro vivo patient-derived direct detection drug-resistant samples from transgenic (Figure 1). It also discusses main mechanisms discovered based these provides model basis possible future personalized They found easier to establish corresponding experimental higher stability reproducibility. individual differences gene expression could reflected; retain characteristics crucial studying pathways related different subtypes; simpler method screening genes; editing can used generate gene-engineered cell lines or animal specific drugs. Therefore, appropriate should selected purpose actual environment.He colleagues (He 2024b)focus radiological influence untreatable progression (UP) time UP (TTUP) local regional interventional This included who received drug-eluting bead TACE (DEB-TACE) hospital January 2017 December 2022. Multivariate logistic regression analysis shows age (OR: 0.950, p=0.044), initial response 0.177, p=0.020), regimen 7.133, p=0.007) three independent risk UP, had greatest impact occurrence UP. Cox total bilirubin (HR: 1.029, p=0.002), distribution 1.752, p=0.034), SACE classification 0.668, p=0.043), number 1.130, p=0.004), 0.539, p=0.019), 4.615, p<0.001) variables affecting TTUP. TTUP was significantly longer than without (329 days vs. 166 days, p<0.05). best (279 130 Subjective Angiographic Chemoembolization Endpoint (SACE) affected TTUP, III IV grades those I II (269 533 70 144 Tumor multi-lobed tumors shorter single-lobed tumors.In years, targeted immunotherapy made significant (Bloom 2025;Hu For instance, drugs targeting FGFR2, IDH1/2, etc. good efficacy trials (Capuozzo 2022;Vogel 2023;He 2024a). Immunotherapy, especially immune checkpoint inhibitors, such as PD-1/PD-L1 demonstrated great (Huang 2025;Liang Local (such TACE, ablation, radioembolization) plays an important role advanced cancer. By optimizing plans, combined ablation effect improved survival period prolonged. In addition, image-guided precise reduce complications improve patient tolerance. Based patient's genetic characteristics, biological behavior features, plans will direction. Through collaboration multidisciplinary teams, considering comprehensively, suitable strategy quality life patients. continuous technology deepening collaboration, diagnosis cancer witness breakthroughs future.

Language: Английский

Citations

0